查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1826556

CD47抑制劑的全球市場:市場機會，各適應症臨床應用，臨床試驗趨勢(2026年)

Global CD47 Inhibitors Drug Market Opportunity, Clinical Application By Indications & Clinical Trials Insight 2026
出版日期: | 出版商: KuicK Research | 英文 230 Pages | 商品交期: 最快1-2個工作天內

價格

全球 CD47 抑制劑市場 - 市場機會、各適應症臨床應用及臨床試驗趨勢（2026 年）報告結果及亮點

  • 研究方法
  • 首個 CD47 抑制劑將於 2028 年獲批
  • CD47 抑制劑各適應症臨床應用及發展前景
  • 臨床試驗中 CD47 抑制劑數量：超過 80 種藥物
  • CD47 抑制劑臨床試驗洞察：按公司、國家、適應症和階段劃分
  • 全球 CD47 抑制劑市場機會展望：當前趨勢與未來前景
  • 突破性療法、快速通道、優先治療和孤兒藥現狀洞察

CD47 抑制劑的需求抑制劑及其報告意義

新型癌症治療的探索重點在於CD47通路，這是一個免疫檢查點，使癌症能夠逃避免疫系統的攻擊。 CD47可以被描述為癌細胞發出的 "別吃我" 的信號，以防止被巨噬細胞（先天免疫系統的關鍵組成部分）清除。這使得CD47成為多種血液系統惡性腫瘤和實體腫瘤的有希望的治療標靶。雖然PD-1/PD-L1抑制劑已取得顯著進展，但許多患者對其治療無效或產生抗藥性。

本報告全面回顧了CD47標靶治療的全球市場，涵蓋了目前正在探索的各種藥物，包括單株抗體、雙特異性抗體、抗體-藥物偶聯物、奈米抗體和小分子。本書涵蓋了不斷發展的臨床前景、標靶CD47的理論基礎以及這類新型療法的商業機會。本報告整合了正在進行的臨床試驗、技術發展和關鍵參與者的信息，為利益相關者（從研發專業人員到投資者和製藥行業領導者）提供了他們在這個快速發展的領域中探索所需的知識。

本報告關於CD47標靶藥物臨床試驗的見解

本報告的核心是一份全面的臨床開發項目列表，這些項目評估了針對多種癌症適應症的CD47標靶藥物。報告列出了從I期到III期的臨床試驗，並提供了地理分佈、資助機構、研究設計和終點資訊。正在進行的針對非何杰金氏淋巴瘤和急性髓性白血病等血液系統惡性腫瘤以及肺癌、結直腸癌、卵巢癌和乳腺癌等實體瘤的研究，顯示全球對CD47標靶療法的廣泛興趣。

本報告強調了人們日益增長的觀點，即CD47抑制劑與其他免疫療法、化療或標靶療法聯合使用效果最佳。本報告探討了臨床試驗終點，例如總存活期、無惡化存活期和緩解率，以及安全性和耐受性評估——所有這些關鍵參數都決定監管部門的批准和臨床應用。這些試驗的新發現凸顯了CD47阻斷療法的前景和局限性，尤其是在控制貧血和血小板減少等脫靶毒性方面。

本節簡要介紹目前的臨床進展，以幫助決策者了解CD47標靶療法的競爭態勢，以及臨床試驗結果如何為CD47標靶療法的未來發展策略提供參考。

從事CD47標靶療法研發的重點公司

CD47治療領域以密集的研發活動為特徵，無數公司正在推動創新，力求達到新的高度。本報告介紹了投資 CD47 研究的領先生物技術和製藥公司，包括吉利德科學 (Gilead Sciences)、ALX Oncology、天境生物 (I-Mab Biopharma)、康方生物 (Akeso Biopharma)、Phanes Therapeutics 和 Liminatus Pharma。這些公司正在研究一系列療法，從第一代單株抗體到下一代雙特異性抗體和小分子抑制劑，旨在提高特異性、最大限度地減少副作用並最大限度地提高療效。

本報告探討了這些公司如何利用專有技術實現差異化，例如用於限制免疫相關毒性的 Fc 區工程、增強腫瘤選擇性和親和力的策略，以及奈米顆粒和載體等新型遞送系統。報告還重點介紹了推動 CD47 科學臨床應用的策略聯盟和許可協議。了解競爭格局和技術差異化因素，有助於利害關係人預測，隨著越來越多的療法接近監管里程碑，哪些進入者最有可能佔市場主導地位。

一份揭示CD47標靶治療未來方向的報告

本報告展望未來，並預測了影響CD47標靶治療方向的幾個關鍵趨勢。安全性和選擇性仍然是主要課題。未來的治療可能旨在優化免疫參與，以最佳方式根除腫瘤，同時降低血液學毒性。同時針對CD47和腫瘤特異性抗原的雙特異性抗體和多功能融合蛋白的出現，可能會改善治療方案和療效。

能夠根據CD47表達和免疫微環境對患者進行準確分層的生物標記指導策略可能會變得越來越重要。這種個人化策略可以提高緩解率，並避免不必要地接觸潛在的毒性療法。將CD47抑制劑與傳統免疫療法或化療結合的聯合療法很可能成為標準治療方法，尤其是對於難治性癌症。

此外，從血液系統惡性腫瘤到實體腫瘤的擴展代表著巨大的成長機會。奈米技術和基因編輯等藥物遞送平台的發展將帶來新的治療機會，並有可能實現長期緩解或治癒。隨著後期臨床數據的湧現和監管途徑的日益清晰，CD47靶向治療市場有望實現顯著增長，並為全球癌症免疫治療的未來鋪平道路。

目錄

第1章 調查手法

第2章 CD47 作為癌症免疫治療的新標靶

第3章 CD47臨床應用和各適應症的開發展望

  • 固體癌
    • 乳癌
    • 消化器官癌症
    • 肺癌症
    • 泌尿生殖系統及婦產科癌症
    • 頭頸椎癌症
  • 造血惡性腫瘤
    • 淋巴瘤
    • 白血病
    • 多發性骨髓瘤
    • 骨髓發育不良症候群
  • 微生物感染疾病
  • 心血管疾病

第4章 全球CD47抑制劑的臨床實驗平台概要

  • 各國
  • 各企業
  • 各適應症
  • 各期
  • 優先各狀態

第5章 CD47抑制劑的臨床試驗:企業，國家，適應症，各期

  • 研究
  • 前臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第二/三階段
  • 第三階段

第6章 全球CD47抑制劑市場機會展望

  • 目前市場概要
  • 未來展望和機會

第7章 CD47抑制劑臨床開發與各國的趨勢

  • 中國
  • 美國
  • 韓國
  • 澳洲
  • 加拿大

第8章 全球CD47抑制劑市場動態

第9章 競爭情形

  • Adagene
  • Akeso
  • ALX Oncology
  • Chia Tai Tianqing Pharmaceutical Group
  • EpicentRx
  • ImmuneOncia Therapeutics
  • ImmuneOnco Biopharma
  • Light Chain Bioscience
  • Phanes Therapeutics
  • Virtuoso Therapeutics

Global CD47 Inhibitors Drug Market Opportunity, Clinical Application By Indications & Clinical Trials Insight 2026 Report Findings & Highlights:

  • Research Methodology
  • First CD47 Inhibitor Drug Approval By 2028
  • CD47 Clinical Application & Development Outlook By Indication
  • Number Of CD47 Inhibitors Drugs In Clinical Trials: > 80 Drugs
  • CD47 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase
  • Global CD47 Inhibitor Drug Market Opportunity Outlook: Current Trends & Future Scenario
  • Breakthrough therapy, Fast Track, PRIME & Orphan Status Insight

Need For CD47 Targeted Therapies & Why This Report

The quest for new cancer treatments has highlighted the CD47 pathway, an immune checkpoint that enables cancer to escape attack by the immune system. CD47 can be called the "don't eat me" signal that cancer cells emit to prevent elimination by macrophages, a key element of the innate immune system. This renders CD47 a very promising therapeutic target for a broad panel of hematologic malignancies and solid tumors. While PD-1/PD-L1 inhibitors have shown significant progress, numerous patients do not respond or become resistant, emphasizing the pressing need for new modalities such as CD47 blockade to further expand the reach of immunotherapy.

This report provides an exhaustive review of the worldwide market for CD47 targeted therapy, covering the heterogeneity of drug formats being explored, such as monoclonal antibodies, bispecific antibodies, antibody drug conjugates, nanobodies and small molecules. It covers the changing clinical landscape, the rationale for targeting CD47, and commercial opportunity for this new class of therapy. Through aggregating information regarding active clinical trials, technological developments, and major players, the report empowers stakeholders from researchers and clinicians to investors and pharmaceutical industry leaders with the understanding required to navigate this quickly developing space.

CD47 Targeted Therapies Clinical Trials Insight Covered In the Report

At the epicenter of this report is an exhaustive list of clinical development programs assessing CD47-targeted therapies for multiple cancer indications. It lists trials ranging from Phase-I to Phase-III stages, offering information on their geographical distribution, sponsoring agencies, trial design, and endpoints. The global view showcases the extensive interest in targeting CD47 therapeutically, with ongoing studies covering hematologic malignancies like non-Hodgkin lymphoma and acute myeloid leukemia and solid tumors like lung, colorectal, ovarian, and breast cancers.

The report covers trials assessing combination approaches, which is a sign of the increasing belief that CD47 inhibitors are best utilized when combined with other immunotherapies, chemotherapies, or targeted treatments. The report offers an evaluation of trial endpoints such as overall survival, progression-free survival, and response rates, together with safety and tolerability measurements, all of which are major parameters determining regulatory approvals and clinical adoption. Emerging reports from these trials highlight the potential and pitfalls of CD47 blockade, specifically in controlling on-target toxicities such as anemia and thrombocytopenia.

By presenting a snapshot of current clinical advances, this section equips decision-makers to grasp where the therapeutic contenders are at and how clinical trial results are informing future development trajectories for CD47-targeted therapies.

Key Companies Engaged In R&D For CD47 Targeted Therapies

The therapeutic space of CD47 is characterized by high research and development activity spearheaded by a myriad of companies driving innovation to new heights. This report identifies leading biotech and pharma companies that are committed to investing in CD47 research such as Gilead Sciences, ALX Oncology, I-Mab Biopharma, Akeso Biopharma, Phanes Therapeutics, and Liminatus Pharma. These firms are investigating a range of therapeutic modalities, from first-generation monoclonal antibodies to next-generation bispecifics and small-molecule inhibitors aimed at enhancing specificity, minimizing side effects, and maximizing efficacy.

The report discusses how these firms are differentiating themselves based on proprietary technologies such as engineered Fc regions to restrict immune-related toxicity or strategies to enhance tumor selectivity and binding, or new delivery systems such as nanoparticles and vectors. It also addresses strategic alliances and licensing agreements that are propelling the translation of CD47 science into clinical assets. A grasp of the competitive landscape and technological differentiators facilitates stakeholders to estimate which players are best suited to rule the market as more therapies near regulatory milestones.

Report Suggesting Future Direction Of CD47 Targeted Therapies Treatment

Looking to the future, the report predicts a number of major trends that will shape the course of CD47-targeting therapies. Safety and selectivity are still major challenges; future therapies will most probably aim to hone immune engagement for optimal tumor eradication with decreased hematologic toxicities. The emergence of bispecific antibodies and multi-functional fusion proteins with the ability to target CD47 as well as tumor-specific antigens simultaneously is likely to enhance therapeutic windows and outcomes.

Biomarker-guided strategies will become increasingly prominent, allowing for the accurate stratification of patients according to CD47 expression and immune microenvironment. Such a personalized strategy can enhance response and prevent unnecessary exposure to potentially toxic treatments. Combination therapies combining CD47 inhibitors with conventional immunotherapies and chemotherapy are likely to become the norm, particularly in the case of therapy-resistant cancers.

In addition, the expansion into solid tumors from hematologic malignancies is a huge opportunity for growth. Inventions in drug delivery platforms, such as nanotechnology and gene editing, could realize new therapeutic opportunities, potentially leading to long-term remission or cure. With late-stage clinical data on the horizon and regulatory pathways becoming more defined, the CD47-targeted therapy market stands to enjoy huge growth, setting the future of cancer immunotherapy on a global level.

Table of Contents

1. Research Methodology

2. CD47 As Novel Cancer Immunotherapy Target

3. CD47 Clinical Application & Development Outlook By Indication

  • 3.1 Solid Cancers
    • 3.1.1 Breast Cancer
    • 3.1.2 Gastrointestinal Cancer
    • 3.1.3 Lung Cancer
    • 3.1.4 Urogenital & Gynecologic Cancers
    • 3.1.5 Head & Neck Cancer
  • 3.2 Hematological Malignancies
    • 3.2.1 Lymphoma
    • 3.2.2 Leukemia
    • 3.2.3 Multiple Myeloma
    • 3.2.4 Myelodysplastic syndrome
  • 3.3 Microbial Infections
  • 3.4 Cardiovascular Diseases

4. Global CD47 Inhibitors Drug Clinical Pipeline Overview

  • 4.1 By Country
  • 4.2 By Company
  • 4.3 By Indication
  • 4.4 By Phase
  • 4.5 By Priority Status

5. CD47 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase

  • 5.1 Research
  • 5.2 Preclinical
  • 5.3 Phase I
  • 5.4 Phase I/II
  • 5.5 Phase II
  • 5.6 Phase II/III
  • 5.7 Phase III

6. Global CD47 Inhibitor Drug Market Opportunity Outlook

  • 6.1 Current Market Overview
  • 6.2 Future Outlook & Opportunities

7. CD47 Inhibitor Drugs Clinical Developments & Trends By Country

  • 7.1 China
  • 7.2 US
  • 7.3 South Korea
  • 7.4 Australia
  • 7.5 Canada

8. Global CD47 Inhibitors Market Dynamics

  • 8.1 Favorable Parameters
  • 8.2 Market Restraints

9. Competitive Landscape

  • 9.1 Adagene
  • 9.2 Akeso
  • 9.3 ALX Oncology
  • 9.4 Chia Tai Tianqing Pharmaceutical Group
  • 9.5 EpicentRx
  • 9.6 ImmuneOncia Therapeutics
  • 9.7 ImmuneOnco Biopharma
  • 9.8 Light Chain Bioscience
  • 9.9 Phanes Therapeutics
  • 9.10 Virtuoso Therapeutics

List of Figures

  • Figure 2-1: CD47-SIRPa Axis & Its Role In Immune Evasion
  • Figure 2-2: CD47 Blockade - Mechanisms Of Action
  • Figure 2-3: CD47 Targeted Therapies - Development Timeline
  • Figure 3-1: PRE-I-SPY-PI Phase I Study (NCT05868226) - Initiation & Completion Year
  • Figure 3-2: I-SPY 2 Phase I Study (NCT01042379) - Initiation & Completion Year
  • Figure 3-3: ZWI-ZW25-204 1/2 Phase I Study (NCT05027139) - Initiation & Completion Year
  • Figure 3-4: LCB-1801-001 Phase I Study (NCT05403554) - Initiation & Completion Year
  • Figure 3-5: AK112-206 Phase II Study (NCT05382442) - Initiation & Completion Year
  • Figure 3-6: AT148006 Phase II/III Study (NCT05002127) - Initiation & Completion Year
  • Figure 3-7: TWINPEAK Phase I/II Study (NCT05482893) - Initiation & Completion Year
  • Figure 3-8: AK104-219 Phase II Study (NCT05960955) - Initiation & Completion Year
  • Figure 3-9: AK117-202 Phase I/II Study (NCT05214482) - Initiation & Completion Year
  • Figure 3-10: SKYBRIDGE Phase I/II Study (NCT05652686) - Initiation & Completion Year
  • Figure 3-11: HCC 21-193 Phase I/II Study (NCT05652686) - Initiation & Completion Year
  • Figure 3-12: HCB101-101 Phase I Study (NCT05892718) - Initiation & Completion Year
  • Figure 3-13: NCI-2021-08492 Phase I/II Study (NCT05025800) - Initiation & Completion Year
  • Figure 3-14: NCI-2022-06277 Phase II Study (NCT05507541) - Initiation & Completion Year
  • Figure 3-15: AK117-104 Phase I/II Study (NCT04980885) - Initiation & Completion Year
  • Figure 3-16: AK117-206 Phase I/II Study (NCT06387420) - Initiation & Completion Year
  • Figure 3-17: BHARAT-1 Phase I Study (NCT05607199) - Initiation & Completion Year
  • Figure 3-18: MagnetisMM-20 Phase I Study (NCT05675449) - Initiation & Completion Year
  • Figure 3-19: 21-122 Phase I Study (NCT05139225) - Initiation & Completion Year
  • Figure 3-20: U1111-1244-2598 Phase I/II Study (NCT04643002) - Initiation & Completion Year
  • Figure 3-21: AK117-103 Phase I/II Study (NCT04900350) - Initiation & Completion Year
  • Figure 3-22: AK117-205 Phase II Study (NCT06196203) - Initiation & Completion Year
  • Figure 4-1: Global - Number of CD47 Inhibitor Drugs Clinical Trial By Country, 2025 - 2026
  • Figure 4-2: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Company, 2025 - 2026
  • Figure 4-3: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Indication, 2025 - 2026
  • Figure 4-4: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Phase, 2025 - 2026
  • Figure 4-5: Global - Number of CD47 Inhibitor Drugs In Clinical Pipeline By Priority Status, 2025 - 2026
  • Figure 6-1: CD47 Targeted Therapy - Future Opportunities
  • Figure 8-1: Global CD47 Inhibitors Market - Drivers & Opportunities
  • Figure 8-2: Global CD47 Inhibitors Market - Challenges & Restraints